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Introduction
In distinct contrast to preventable anaesthetic mortality, 
which thankfully is now rare, all-cause postoperative 
mortality is surprisingly high. Approximately 5% of surgical 
patients die in the year following surgery. Mortality is roughly 
10% in those who are older than 65 years of age.1 In other 
words, mortality in the year after surgery is approximately 
10 000 times more common than preventable anaesthetic 
mortality. 
Thus, it is reasonable to ask to what extent anaesthetic 
management might influence long-term outcomes. The 
distinction being made here is between the classical 
definition of anaesthetic complications, which is restricted 
to the immediate perioperative period, perhaps extending 
to a few days after surgery, and the potential effects of 
anaesthetic management on events weeks, months or even 
years after surgery. 
Given that modern anaesthetic drugs are uniformly short 
acting, it is by no means obvious that the consequences of 
anaesthetic management could last more than hours or days 
after surgery. The long-term consequences of anaesthesia 
were not seriously considered until relatively recently. There 
is increasing evidence that some intraoperative anaesthetic 
management decisions have long-term consequences, and 
that others might as well.
Surgical site infection
Arguably, the first convincing evidence of long-term 
outcomes that relate to anaesthetic management dates 
to 1996 when two key articles were published in the 
New England Journal of Medicine.  Mangano et  al linked 
perioperative beta-blocker administration to myocardial 
infarction and mortality.2 Kurz et  al showed that mild 
hypothermia tripled the risk of surgical wound infection,3 
even though surgical site infections become clinically 
apparent 1-4 weeks after surgery. The link between 
hypothermia and infection was subsequently confirmed by 
an additional randomised trial.4 The risk of surgical wound 
infection also appeared to be moderated by supplemental 
oxygen, even when supplemental oxygen was only provided 
during surgery, and at two5 or six6 hours thereafter.
Thus, there is considerable evidence that wound infections, 
despite becoming clinically apparent weeks after surgery, 
are established during and immediately after surgery. 
Surgical wounds become contaminated and surgical sterility 
is only relative! Whether or not contamination progresses 
to clinical infection is determined by the adequacy of host 
defenses during a decisive period that lasts several hours 
after contamination. The most important host defense is 
oxidative killing by neutrophils in the case of bacteria which 
causes surgical wound infections.7 This process requires 
molecular oxygen8 and is a function of tissue, as opposed to 
arterial oxygen partial pressure over the entire physiological 
range. Interventions which increase tissue oxygen during 
the decisive period, such as maintaining normothermia9 and 
providing supplemental oxygen,5 reduce the progression of 
contamination to clinical infection. 
It is likely that infection risk is similarly diminished by 
other factors that support tissue oxygenation,10 including 
adequate sympathetic block11 and good control of surgical 
pain.12 The potential benefit of these and other interventions 
has yet to be determined in large-scale outcome studies, 
but remain under active investigation. 
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Regional analgesia and cancer 
recurrence
Cancer is an additional long-term outcome that needs to 
be considered. Although not widely appreciated, tumour 
surgery is usually associated with the release of tumour 
cells into the lymphatic and blood streams. Furthermore, a 
large fraction of patients already harbour micrometastases 
and scattered tumour cells at the time of surgery.13 Whether 
this minimal residual disease results in clinical metastases 
depends largely on the balance between antimetastatic 
immune activity and the tumour’s ability to seed, proliferate 
and attract new blood vessels.14 
At least three perioperative factors shift the balance towards 
the progression of minimal residual disease:
•	 The first is surgery, which releases tumour cells into 
circulation;13 depresses cell-mediated immunity (includ-
ing cytotoxic T-cell and natural killer cell functions);15 
reduces circulating concentrations of tumour-related 
antiangiogenic factors; increases concentrations of 
proangiogenic factors, such as vascular endothelial 
growth factor;16 and releases growth factors which pro-
mote the local and distant growth of malignant tissue.14 
•	 The second factor is that anaesthesia impairs neutrophil, 
macrophage, dendritic cell, T-cell, and natural killer cell 
immune functions.17 
•	 The third is opioids which inhibit both cellular and 
humoral immune function.17 Furthermore, morphine is 
proangiogenic and promotes breast tumour growth.18 
Consequently, non-opioid analgesia helps to preserve 
natural killer cell function in animals and humans, and 
reduces the metastatic spread of cancer in rodents.19 
Regional anaesthesia and analgesia (postoperative 
pain relief) attenuate or prevent each of these adverse 
effects. For example, regional anaesthesia largely 
prevents the neuroendocrine stress response to surgery 
by blocking afferent neural transmission from reaching 
the central nervous system, and by blocking descending 
efferent activation of the sympathetic nervous system.20 
Consequently, natural killer cell function is better preserved 
with regional anaesthesia, and metastatic load to the lungs 
reduced in a rat model of breast cancer metastasis.15 
When regional and general anaesthesia are combined, the 
amount of general anaesthetic required is greatly reduced, as 
is immune suppression presumably. Furthermore, regional 
analgesia provides superb pain relief, essentially obviating 
the need for postoperative opioids and consequent adverse 
effects on immune function and of tumour growth.17,20 
Regional analgesia also reduces the release of endogenous 
opioids.21 
Thus, available data suggest that regional anaesthesia and 
analgesia help to preserve effective defenses against tumour 
progression by attenuating the surgical stress response, by 
reducing general anaesthesia requirements and by sparing 
postoperative opioids.22 Animal studies are consistent 
with this theory, showing that regional anaesthesia and 
optimum postoperative analgesia independently reduce 
the metastatic burden in animals inoculated with breast 
adenocarcinoma cells.23 Available human data, although 
extremely limited, are also consistent with this theory. 
For example, paravertebral anaesthesia and analgesia for 
breast cancer surgery are associated with an approximate 
fourfold reduced risk of recurrence or metastasis.24 Similarly, 
epidural analgesia for radical prostate surgery is associated 
with a 60% reduction in recurrence risk.25 Major prospective 
trials on paravertebral analgesia for breast cancer surgery 
(NCT00418457)26 and epidural analgesia for colon cancer 
are in progress (NCT00684229).
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